GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars

FDA Slaps Refusal to File Letter on Soligenix’s Photodynamic Cancer Therapy Application

by Reed Slater
Share To

After Soligenix submitted a New Drug Application (NDA) for its proprietary photodynamic therapy to treat cutaneous T-cell lymphoma (CTCL), HyBryte, the FDA responded with a Refusal to File (RTF) letter. The New Jersey-based company said it plans to request a Type A meeting with the FDA to seek guidance from the regulatory agency to correct any issues or insufficiencies for a new application. 

HyBryte’s Promising Track Record

Soligenix designed HyBryte to treat CTCL using safe, visible light to activate synthetic hypericin, a photosensitizer topically applied to skin lesions. The company says the red-yellow spectrum that HyBryte uses penetrates the skin deep enough to treat deeper skin disease, thicker plaque, and lesions. 

Since starting development on HyBryte, the FDA granted Fast Track Designation and Orphan Drug Designation for the therapy. Soligenix recently published results from the Phase 3 FLASH trial demonstrating positive results in CTCL patients.

The FLASH trial consisted of three treatment cycles for 169 participants. After the first cycle, 16% of 116 patients receiving HyBryte achieved at least a 50% reduction in lesions. Responses from the second cycle increased to 40%, and the third cycle elicited positive responses from 49% of participants. 

Related Article: Biocon and Viatris Hit Another FDA Wall with Avastin Biosimilar

Opening the FDA’s RTF Letter

Still, even with the impressive results, the FDA did not accept the company’s December NDA for the drug. The FDA does not make RTF letters public, but Soligenix issued a press release addressing the matter, stating the FDA did not find the application sufficiently complete upon preliminary review. 

In response, the company said it intends to work with FDA staff to identify and remediate issues with the current application to submit a new NDA for HyBryte. 

President and CEO of Soligenix, Christopher J. Schaber, PhD., said, “We are fully determined to work with the FDA staff as quickly as possible to better understand the open issues and clarify the potential path to successfully resubmitting our application.”

In time, Soligenix hopes to have a clear path forward to bring HyBryte to the market, providing a novel and exciting new treatment method for CTCL. The company will have to wait a bit longer than it intended to fix any issues with its initial NDA filing. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top